⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31739482 | 0.79 | — | — | |
| SCHEMBL25339293 | 0.79 | CXCR4 (0.34) | — | |
| SCHEMBL31460354 | 0.78 | — | — | |
| SCHEMBL30793973 | 0.77 | — | — | |
| SCHEMBL30793992 | 0.76 | CHRNB2 (0.32) | — | |
| SCHEMBL29777623 | 0.76 | THRB (0.33) | — | |
| SCHEMBL25338104 | 0.71 | PDE4A (0.34) | — | |
| SCHEMBL24535154 | 0.71 | CXCR4 (0.30) | — | |
| SCHEMBL26943913 | 0.71 | PDCD1 (0.35) | — | |
| SCHEMBL20939740 | 0.70 | CYP11B1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262807-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-116829151-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |